Tag: Biotech and Pharma

Novo Nordisk’s weight-loss pill exceeds forecasts, closing gap with Lilly

Novo Nordisk, opens new tab beat first-quarter profit forecasts and nudged up its full-year outlook on Wednesday, helped by stronger-than-expected sales of its new weight-loss pill ‌as it seeks to close the gap with U.S. rival Eli Lilly.

Pfizer Stock Rises on Earnings. The Drugmaker Is Finding Life After Covid.

Pfizer shares climbed on Tuesday after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook.

Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

Moderna defied expectations of a Covid-revenue slowdown on Friday as the drugmaker delivered strong first-quarter results fueled by a surge in international vaccine sales.

Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook

Bristol-Myers Squibb reported first-quarter earnings and revenue that topped analyst expectations, and reaffirmed its outlook for the full year.

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket

Shares of Eli Lilly (LLY) rose sharply Thursday after the drugmaker delivered a beat-and-raise quarter driven partly by demand for its GLP-1 drugs.

GSK Earnings Boosted by Higher Specialty Medicine Sales

GSK (GSK) reported higher earnings on increased specialty medicine sales and said it expects to pay a total dividend this year of 70 pence a share.

AstraZeneca beats profit estimates, backs 2026 outlook on strong cancer drug sales

AstraZeneca (AZN)  beat first-quarter profit expectations and maintained its 2026 forecasts on Wednesday, supported by strong demand for its cancer and rare-disease drugs and investments in the key U.S. and China markets.

Novartis Earnings Hit by Generic Competition

Novartis (NOVN) reported a drop in earnings as generic competition for its top-selling heart drug Entresto hit sales in the first months of the year.

Lavipharm: Ισχυρή ανάπτυξη με Durogesic και κάνναβη – Οι νέες στρατηγικές κινήσεις

Την Ετήσια Ενημέρωση Αναλυτών πραγματοποίησε σήμερα η Lavipharm A.E. σύμφωνα με το Οικονομικό Ημερολόγιο 2026 της Εταιρείας. Η παρουσίαση πραγματοποιήθηκε στο Χρηματιστήριο Αθηνών, στην Ένωση Θεσμικών Επενδυτών.

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion

 Eli Lilly (LLY) said on Monday ‌it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 ​billion in cash.

Sanofi’s solid earnings set stage for new CEO after drug trial ‘setbacks’

Sanofi (SASY) beat first-quarter estimates on Thursday as demand for ‌its asthma and eczema drug Dupixent remained high, though analysts looked to incoming CEO Belén Garijo to ignite growth beyond the blockbuster drug.

Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment

Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.

Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire ​biotech firm Kelonia Therapeutics for more than $2 ‌billion, the Wall Street Journal reported on Sunday.

Abbott shares dip on soft current-quarter guide; Q1 results in line

Abbott Laboratories reported first-quarter earnings in line with expectations and revenue above forecasts on Wednesday, but shares slipped after the medical device maker issued soft second-quarter profit guidance.

Novo Nordisk partners with OpenAI as AI drug discovery hopes mount

Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday.

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter.

Johnson & Johnson (JNJ) has reinvented itself several times in recent years. In 2021, it was best known as the developer of a Covid vaccine.

Lavipharm: Νέο deal 12 εκατ. δολαρίων – Συμφωνία με την Janssen Global Services

Σε συμφωνία με την Janssen Global Services ήρθε η Lavipharm A.E. για την απόκτηση των δικαιωμάτων του συνταγογραφούμενου διαδερμικού επιθέματος DUROGESIC

Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Revolution Medicines’ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.”

Eli Lilly secures long-awaited FDA approval for its obesity pill. Here’s what to know

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.